Efficacy  ||| S:0 E:9 ||| NNP
and  ||| S:9 E:13 ||| CC
safety  ||| S:13 E:20 ||| NN
evaluation  ||| S:20 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
a  ||| S:34 E:36 ||| DT
novel  ||| S:36 E:42 ||| NN
botulinum  ||| S:42 E:52 ||| NN
toxin  ||| S:52 E:58 ||| NN
topical  ||| S:58 E:66 ||| NN
gel  ||| S:66 E:70 ||| NN
for  ||| S:70 E:74 ||| IN
the  ||| S:74 E:78 ||| DT
treatment  ||| S:78 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
moderate  ||| S:91 E:100 ||| JJ
to  ||| S:100 E:103 ||| TO
severe  ||| S:103 E:110 ||| JJ
lateral  ||| S:110 E:118 ||| JJ
canthal  ||| S:118 E:126 ||| JJ
lines  ||| S:126 E:132 ||| NNS
Botulinum  ||| S:132 E:142 ||| JJ
toxin  ||| S:142 E:148 ||| NN
type  ||| S:148 E:153 ||| NN
A  ||| S:153 E:155 ||| DT
( ||| S:155 E:156 ||| -LRB-
BoNTA ||| S:156 E:161 ||| NNP
)  ||| S:161 E:163 ||| -RRB-
is  ||| S:163 E:166 ||| VBZ
commonly  ||| S:166 E:175 ||| RB
injected  ||| S:175 E:184 ||| VBN
to  ||| S:184 E:187 ||| TO
treat  ||| S:187 E:193 ||| VB
facial  ||| S:193 E:200 ||| JJ
wrinkles ||| S:200 E:208 ||| NN
.  ||| S:208 E:210 ||| .
Complications  ||| S:210 E:224 ||| NNS
include  ||| S:224 E:232 ||| VBP
pain ||| S:232 E:236 ||| NN
,  ||| S:236 E:238 ||| ,
erythema ||| S:238 E:246 ||| NN
,  ||| S:246 E:248 ||| ,
bruising ||| S:248 E:256 ||| VBG
,  ||| S:256 E:258 ||| ,
and  ||| S:258 E:262 ||| CC
potential  ||| S:262 E:272 ||| JJ
infection ||| S:272 E:281 ||| NN
.  ||| S:281 E:283 ||| .
RT001  ||| S:283 E:289 ||| NNP
Botulinum  ||| S:289 E:299 ||| NNP
Toxin  ||| S:299 E:305 ||| NNP
Type  ||| S:305 E:310 ||| NNP
A  ||| S:310 E:312 ||| NNP
Topical  ||| S:312 E:320 ||| NNP
Gel  ||| S:320 E:324 ||| NNP
( ||| S:324 E:325 ||| -LRB-
RT001 ||| S:325 E:330 ||| NNP
)  ||| S:330 E:332 ||| -RRB-
is  ||| S:332 E:335 ||| VBZ
under  ||| S:335 E:341 ||| IN
development  ||| S:341 E:353 ||| NN
for  ||| S:353 E:357 ||| IN
the  ||| S:357 E:361 ||| DT
treatment  ||| S:361 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
lateral  ||| S:374 E:382 ||| JJ
canthal  ||| S:382 E:390 ||| JJ
lines  ||| S:390 E:396 ||| NNS
( ||| S:396 E:397 ||| -LRB-
LCLs ||| S:397 E:401 ||| NNP
) ||| S:401 E:402 ||| -RRB-
.  ||| S:402 E:404 ||| .
To  ||| S:404 E:407 ||| TO
assess  ||| S:407 E:414 ||| VB
the  ||| S:414 E:418 ||| DT
efficacy  ||| S:418 E:427 ||| NN
and  ||| S:427 E:431 ||| CC
safety  ||| S:431 E:438 ||| NN
of  ||| S:438 E:441 ||| IN
RT001  ||| S:441 E:447 ||| CD
for  ||| S:447 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
treatment  ||| S:455 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
LCLs  ||| S:468 E:473 ||| JJ
using  ||| S:473 E:479 ||| VBG
a  ||| S:479 E:481 ||| DT
randomized ||| S:481 E:491 ||| NN
,  ||| S:491 E:493 ||| ,
double-blind ||| S:493 E:505 ||| NNP
,  ||| S:505 E:507 ||| ,
repeat-dose ||| S:507 E:518 ||| NNP
,  ||| S:518 E:520 ||| ,
placebo-controlled  ||| S:520 E:539 ||| JJ
study  ||| S:539 E:545 ||| NN
design ||| S:545 E:551 ||| NN
.  ||| S:551 E:553 ||| .
Healthy  ||| S:553 E:561 ||| JJ
adult  ||| S:561 E:567 ||| NN
subjects  ||| S:567 E:576 ||| NNS
were  ||| S:576 E:581 ||| VBD
randomized  ||| S:581 E:592 ||| VBN
to  ||| S:592 E:595 ||| TO
receive  ||| S:595 E:603 ||| VB
RT001  ||| S:603 E:609 ||| NNP
( ||| S:609 E:610 ||| -LRB-
N=19 ||| S:610 E:614 ||| NNP
)  ||| S:614 E:616 ||| -RRB-
or  ||| S:616 E:619 ||| CC
placebo  ||| S:619 E:627 ||| NNS
( ||| S:627 E:628 ||| -LRB-
N=17 ||| S:628 E:632 ||| NNP
)  ||| S:632 E:634 ||| -RRB-
applied  ||| S:634 E:642 ||| VBD
to  ||| S:642 E:645 ||| TO
their  ||| S:645 E:651 ||| PRP$
lateral  ||| S:651 E:659 ||| JJ
canthal  ||| S:659 E:667 ||| JJ
areas  ||| S:667 E:673 ||| NNS
( ||| S:673 E:674 ||| -LRB-
LCAs ||| S:674 E:678 ||| NNP
) ||| S:678 E:679 ||| -RRB-
.  ||| S:679 E:681 ||| .
To  ||| S:681 E:684 ||| TO
evaluate  ||| S:684 E:693 ||| VB
safety  ||| S:693 E:700 ||| NN
of  ||| S:700 E:703 ||| IN
repeat  ||| S:703 E:710 ||| NN
exposure ||| S:710 E:718 ||| NN
,  ||| S:718 E:720 ||| ,
treatment  ||| S:720 E:730 ||| NN
was  ||| S:730 E:734 ||| VBD
administered  ||| S:734 E:747 ||| VBN
at  ||| S:747 E:750 ||| IN
baseline  ||| S:750 E:759 ||| NN
and  ||| S:759 E:763 ||| CC
week  ||| S:763 E:768 ||| NN
4 ||| S:768 E:769 ||| CD
.  ||| S:769 E:771 ||| .
The  ||| S:771 E:775 ||| DT
primary  ||| S:775 E:783 ||| JJ
efficacy  ||| S:783 E:792 ||| JJ
measure  ||| S:792 E:800 ||| NN
was  ||| S:800 E:804 ||| VBD
improvement  ||| S:804 E:816 ||| NN
in  ||| S:816 E:819 ||| IN
baseline  ||| S:819 E:828 ||| JJ
LCL  ||| S:828 E:832 ||| NNP
severity  ||| S:832 E:841 ||| NN
using  ||| S:841 E:847 ||| VBG
the  ||| S:847 E:851 ||| DT
Investigator ||| S:851 E:863 ||| NNP
's  ||| S:863 E:866 ||| POS
Global  ||| S:866 E:873 ||| NNP
Assessment  ||| S:873 E:884 ||| NNP
of  ||| S:884 E:887 ||| IN
Lateral  ||| S:887 E:895 ||| NNP
Canthal  ||| S:895 E:903 ||| NNP
Line  ||| S:903 E:908 ||| NNP
at  ||| S:908 E:911 ||| IN
Rest  ||| S:911 E:916 ||| NNP
( ||| S:916 E:917 ||| -LRB-
IGA-LCL ||| S:917 E:924 ||| NNP
)  ||| S:924 E:926 ||| -RRB-
Severity  ||| S:926 E:935 ||| NNP
Scale ||| S:935 E:940 ||| NNP
.  ||| S:940 E:942 ||| .
At  ||| S:942 E:945 ||| IN
8  ||| S:945 E:947 ||| CD
weeks ||| S:947 E:952 ||| NNS
,  ||| S:952 E:954 ||| ,
19  ||| S:954 E:957 ||| CD
( ||| S:957 E:958 ||| -LRB-
50 ||| S:958 E:960 ||| CD
% ||| S:960 E:961 ||| NN
)  ||| S:961 E:963 ||| -RRB-
LCAs  ||| S:963 E:968 ||| JJ
treated  ||| S:968 E:976 ||| NN
with  ||| S:976 E:981 ||| IN
RT001  ||| S:981 E:987 ||| NNP
showed  ||| S:987 E:994 ||| VBD
a  ||| S:994 E:996 ||| DT
2-point  ||| S:996 E:1004 ||| NNP
or  ||| S:1004 E:1007 ||| CC
greater  ||| S:1007 E:1015 ||| JJR
improvement  ||| S:1015 E:1027 ||| NN
in  ||| S:1027 E:1030 ||| IN
baseline  ||| S:1030 E:1039 ||| JJ
IGA-LCL  ||| S:1039 E:1047 ||| JJ
severity ||| S:1047 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
versus  ||| S:1057 E:1064 ||| CC
none  ||| S:1064 E:1069 ||| NN
( ||| S:1069 E:1070 ||| -LRB-
0 ||| S:1070 E:1071 ||| CD
% ||| S:1071 E:1072 ||| NN
)  ||| S:1072 E:1074 ||| -RRB-
of  ||| S:1074 E:1077 ||| IN
the  ||| S:1077 E:1081 ||| DT
placebo-treated  ||| S:1081 E:1097 ||| JJ
subjects  ||| S:1097 E:1106 ||| NNS
( ||| S:1106 E:1107 ||| -LRB-
p  ||| S:1107 E:1108 ||| FW
< ||| S:1108 E:1109 ||| SYM
.001 ||| S:1109 E:1113 ||| FW
) ||| S:1113 E:1114 ||| -RRB-
;  ||| S:1114 E:1116 ||| :
36  ||| S:1116 E:1119 ||| CD
( ||| S:1119 E:1120 ||| -LRB-
94.7 ||| S:1120 E:1124 ||| NNP
% ||| S:1124 E:1125 ||| NN
)  ||| S:1125 E:1127 ||| -RRB-
LCAs  ||| S:1127 E:1132 ||| JJ
treated  ||| S:1132 E:1140 ||| NN
with  ||| S:1140 E:1145 ||| IN
RT001  ||| S:1145 E:1151 ||| NNP
showed  ||| S:1151 E:1158 ||| VBD
a  ||| S:1158 E:1160 ||| DT
1-point  ||| S:1160 E:1168 ||| NNP
or  ||| S:1168 E:1171 ||| CC
more  ||| S:1171 E:1176 ||| JJR
improvement  ||| S:1176 E:1188 ||| NN
in  ||| S:1188 E:1191 ||| IN
baseline  ||| S:1191 E:1200 ||| JJ
IGA-LCL  ||| S:1200 E:1208 ||| JJ
severity ||| S:1208 E:1216 ||| NN
,  ||| S:1216 E:1218 ||| ,
versus  ||| S:1218 E:1225 ||| CC
five  ||| S:1225 E:1230 ||| CD
( ||| S:1230 E:1231 ||| -LRB-
14.7 ||| S:1231 E:1235 ||| CD
% ||| S:1235 E:1236 ||| NN
)  ||| S:1236 E:1238 ||| -RRB-
placebo-treated  ||| S:1238 E:1254 ||| NNP
LCAs  ||| S:1254 E:1259 ||| NNP
( ||| S:1259 E:1260 ||| -LRB-
p  ||| S:1260 E:1261 ||| FW
< ||| S:1261 E:1262 ||| SYM
.001 ||| S:1262 E:1266 ||| FW
) ||| S:1266 E:1267 ||| -RRB-
.  ||| S:1267 E:1269 ||| .
There  ||| S:1269 E:1275 ||| EX
were  ||| S:1275 E:1280 ||| VBD
no  ||| S:1280 E:1283 ||| DT
treatment-related  ||| S:1283 E:1301 ||| JJ
adverse  ||| S:1301 E:1309 ||| JJ
events ||| S:1309 E:1315 ||| NNS
.  ||| S:1315 E:1317 ||| .
RT001  ||| S:1317 E:1323 ||| NNP
was  ||| S:1323 E:1327 ||| VBD
well  ||| S:1327 E:1332 ||| RB
tolerated  ||| S:1332 E:1342 ||| JJ
and  ||| S:1342 E:1346 ||| CC
demonstrated  ||| S:1346 E:1359 ||| VBD
an  ||| S:1359 E:1362 ||| DT
improvement  ||| S:1362 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
LCLs ||| S:1377 E:1381 ||| JJ
.  ||| S:1381 E:1383 ||| .
